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Abstract
Background: GTPase regulator associated with the focal adhesion kinase (GRAF), a putative tumor suppressor gene,
is found inactivated in hematopoietic malignancies by either genetic or epigenetic abnormalities. However, the
expression level of GRAF gene has not yet been studied in leukemia. The aim of this study was to investigate the
expression level of GRAF gene in those patients with myeloid malignancies including acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML).
Methods: The expression levels of GRAF transcript were determined in 94 patients using real-time quantitative PCR
(RQ-PCR). Clinical and laboratory data of these patients were collected and analyzed.
Results: The significantly decreased level of GRAF transcript was observed in three myeloid malignancies compared
to controls. Within AML, there was no difference in the level of GRAF transcript among different FAB subtypes
(P > 0.05). Difference was not observed in the amount of GRAF mRNA between CML at chronic phase and controls.
As CML progressed, GRAF transcript significantly decreased. In MDS, three cases with 5q deletion had lower GRAF
transcript than four without 5q deletion (median 0.76 vs 2.99) (P > 0.05).
Conclusion: our results demonstrate that the GRAF transcript is decreased in myeloid malignancies.
Background
Focal adhesion kinase (FAK), a non-receptor tyrosine
kinase that resides at the sites of integrin clustering [1],
plays an important role in the modulation of cell
growth, proliferation, survival and migration [2].
Recently, FAK has been found to be overexpressed and/
or constitutively activated and correlated with increased
motility, invasiveness, and proliferation of neoplastic
cells of various tissue types [2]. Two published articles
revealed that aberrant expression of FAK was observed
in CD34+ leukemic cells and associated with enhanced
blast migration, increased cellularity and poor prognosis
[3,4]. Le et al showed that FAK silencing inhibited leu-
kemogenesis in BCR/ABL-transformed hematopoietic
cells [5]. Tyner et al also identified FAK as one of thera-
peutic molecular targets in acute myeloid leukemia
(AML) [6].
FAK protein is composed of an N-terminal FERM
domain, a central kinase domain, and a C-terminal
domain that includes the focal adhesion targeting (FAT)
sequence responsible for FAK’s localization to focal
adhesions. Both the N-terminal and C-terminal domains
have been shown to mediate FAK interaction with a
variety of other proteins critical for activation of FAK by
integrins or other cell surface receptors as well as FAK
regulation of different cellular functions [2].
GTPase regulator associated with focal adhesion
kinase (GRAF) is a newly identified protein specifically
binding to the proline-rich region in the COOH termi-
nus of FAK and negatively regulates the small GTP-
binding protein RhoA, which is well known for its
growth-promoting effect in RAS-mediated malignant
transformation [7,8]. GRAF gene is located at chromo-
some 5q31 and its protein is ubiquitously expressed in
various tissues [9]. Mutations and deletions of GRAF
gene were found in some cases with AML or myelodys-
plastic syndrome (MDS) with a deletion 5q [9]. Further-
more, Bojesen et al [10] found that GRAF gene
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pressed GRAF expression could be restored in leukemic
cell lines by treatment with a demethyating agent and
an inhibitor of histone deacytylases. However, the
expression level of GRAF gene has not yet been studied
in leukemia. We established the real-time quantitative
polymerase chain reaction (RQ-PCR) assay with Eva-
Green dye and examined the expression level of GRAF
mRNA in myeloid malignancies.
Materials and methods
Patients and samples
The bone marrow mononuclear cells (BMNCs) from 94
patients with myeloid malignancies, including 72 AML,
7 MDS and 15 chronic myeloid leukemia (CML), were
studied. The diagnosis and classification of AML
and MDS patients were based on the French-American-
British (FAB) and World Health Organization (WHO)
criteria (blast ≥ 20%) combined to immunophenotyping
and cytogenetic analysis [11-15]: among AML, 12 cases
of M1, 23 cases of M2, 13 cases of M3, 18 cases of M4,
5 cases of M5, 1 case of M6; among MDS, 1 case of
refractory anemia with ring sideroblasts (RARS), 2 cases
of refractory cytopenia with multilineage dysplasia
(RCMD), 3 cases of refractory anemia with excess
blasts-1 (RAEB-1), 1 case of RAEB-2. The diagnosis of
CML was established according to the conventional cri-
teria [16]: 10 cases at chronic phase (CP), 5 cases at
blast crisis (BC).
The clinical characteristics of patients were listed in
Table 1. Karyotypes were analyzed using conventional
R-banding method. Karyotype risk in AML and MDS
was classified according to the reported studies [15,17].
t(15;17) was also included in the group of low risk.
BMNCs, collected from 3 donors of bone marrow trans-
plantation, 5 patients with immune thrombocytopenia
(ITP), and 13 with iron deficiency anemia (IDA), were
used as controls.
Immunophenotyping studies
Erythrocyte-lysed whole BM samples from 61 AML
patients were analyzed by flow cytometry using a panel
of MoAbs in triple stainings [phycoerythrin (PE)/fluores-
cein isothiocyanate (FITC)/Peridin chlorophyll (PerCP)]:
IgG1-FITC; IgG2a-PE; CD2-PE; CD4-FITC; CD7-FITC;
CD10-FITC; CD11b-PE; CD13-PE; CD19-PE; CD38-PE;
CD45-PerCP; CD117-PE; HLA-DR-FITC (Becton
Dickinson, USA); CD14-PE; CD22-FITC; CD33-FITC;
CD34-FITC; CD36-FITC (Beckman Coulter, USA). Data
acquisition and analysis were performed on a FACScali-
bur flow cytometer (Becton Dickinson) using Cell-Quest
software. Identification of leukemic cells was performed
using CD45 intensity versus SSC dot plots. Antigen
expression was considered to be positive when the per-
centage of positive leukemic cells was equal or greater
than 20%.
Preparation of RNA and cDNA synthesis
BMNCs were separated using Lymphoprep and lysed
with Trizol (In Vitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Two micrograms of
total RNA was reverse transcribed to cDNA in a total
reaction volume of 40 μl containing 5× buffer, dNTPs
10 mM each, random hexamers 10 μM, RNAsin 80 units
and 200 units of MMLV reverse transcriptase (MBI
Fermentas, USA). Samples were incubated for 10 min at
25°C, 60 min at 42°C, and then stored at -20°C.
RQ-PCR
RQ-PCR was performed using EvaGreen dye (BIO-
TIUM, Hayward, CA, USA) on a 7300 Thermo cycler
(Applied Biosystems, Foster City, CA, USA). Real-time
fluorescent data were collected and analyzed with SDS
1.3 software (Applied Biosystems, Foster City, CA,
USA). The baseline fluorescence intensities were fixed at
cycles 6-15 by default and 0.01 was set as the threshold
to determine the cycle threshold (CT) value. The
Table 1 clinical and laboratory features of patients with myeloid malignancies
Parameter AML CML MDS
Age, median (range) (years)
a 54(2-86) 52(11-75) 63(39-85)
Sex (male/female) 44/28 8/7 5/2
WBC (×10
9/l)
a 7.5(0.3-203.6) 83.4(2.8-168.7) 3.6(1.6-12.2)
Haemoglobin (g/dl)
a 71(24-123) 91(50-134) 64(46-91)
Platelet count (×10
9/l)
a 40(3-447) 200(20-850) 50(10-926)
Cytogenetics
Good 22 3
Intermediate 35 3
Poor 8 1
CD34(+/-) 35/26
GRAF level
a 3.88(0.01-169.75)
b 23.51(0.01-157.42)
c 10.20(0.25-45.90)
b
WBC, white blood cells;
aMedian (range);
bP < 0.001, compared with control;
cP = 0.030, compared with control;
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designed against GenBank-published sequences
(NM_015071 and NM_14752) with the software Primer
Express 2.0 (Applied Biosystems, Foster City, CA, USA).
The primer sequences are as follows: GRAF forward 5′-
ATTCCAGCAGCAGCTTACA-3′, reverse 5′-GATGAG
GTGGGCA TAGGG-3′, ABL forward 5′-TCCTCCA
GCTGTTATCTGGAAGA-3′,r e v e r s e5 ′-TCCAACGA
GCGGCTTCAC-3′, with expected PCR products of 166
bp and 118 bp, respectively. PCR was performed in a
final volume of 25 μl, containing 100 ng of cDNA,
0 . 2m Mo fd N T P ,4m Mo fM g C l 2,0 . 4μMo fp r i m e r s ,
1.2 μl of EvaGreen, 1.0 U of Taq DNA Polymerase (MBI
Fermentas, USA). Amplification consisted of an initial
denaturation step of 94°C for 4 min followed by 40
cycles of a denaturation step at 94°C for 30 s, an anneal-
ing step at 62°C for 30 s, an extension step of 72°C for
30 s, and an fluorescence collection step at 82°C for 30
s, followed by a final extension of 72°C for 10 min. Ster-
ile H2O without cDNA used as no-template control
(NTC) in each assay. The copies of GRAF and ABL
mRNA were calculated automatically by the software.
The relative amount of GRAF was normalized using the
following formula: NGRAF = (copies of GRAF/copies of
ABL) × 100. Amplified RQ-PCR products from three
samples were sequenced (Shanghai GeneCore Bio-
Technologies Co., Ltd., China).
Statistical analyses
Statistics was performed using the SPSS 13.0 software
package (SPSS, Chicago, IL). The Kruskal-Wallis test
(multiple groups) and Mann-Whitney U-test (two
groups) were employed to compare the difference
between patient groups and controls. The correlation
between the level of GRAF transcript and the sex, age,
hematologic parameters, FAB subtypes and karyotypic
groups was calculated by Spearman’s rho correlation
analyses. A P-value < 0.05 was considered significant.
Results
GRAF expression in controls and AML patients
The level of GRAF transcript in controls was 14.49-
126.85 (median 56.04). The significantly decreased
level of GRAF transcript was observed in different
myeloid malignancies (Table 1, Figure 1). There was
no correlation between GRAF mRNA amount and the
sex, age, peripheral white blood cell count, hemoglobin
level, and platelet count (P > 0.05). The association of
GRAF levels with cytogenetic abnormalities or CD34
antigen expression was also not observed in AML
patients (P >0 . 0 5 ) .W i t h i nA M L ,t h e r ew a sn od i f f e r -
ence in the level of GRAF transcript among different
FAB subtypes (P > 0.05).
GRAF expression in CML patients
The median levels of GRAF transcript in CML patients
at CP and BC were 46.82 (1.08-157.42) and 10.69 (0.01-
23.51), respectively (Figure 2). There was no difference
in GRAF transcript amount between CML patients at
CP and controls (P >0 . 0 5 ) .H o w e v e r ,t h ea m o u n to f
GRAF mRNA in CML at BC was significantly lower
than that in cases at CP and that in controls (P =0 . 0 2 8
and <0.001, respectively).
GRAF expression in MDS patients
Among MDS patients, three cases were identified with
deletions of 5q (5q-) (Table 2). The level of GRAF
Figure 1 Scatterplot showing varying levels of GRAF transcript
in patients with different myeloid malignancies and controls.
Figure 2 Expression level of GRAF transcript in CML.
Qian et al. Journal of Experimental & Clinical Cancer Research 2010, 29:111
http://www.jeccr.com/content/29/1/111
Page 3 of 5transcript was lower in these cases (0.49-1.02, median
0.76) than the other four cases without 5q- (0.25-45.90,
median 2.99), however, statistical difference was not
observed (P > 0.05).
Discussion
In this study, we demonstrated that the expression
level of GRAF transcript was decreased in primary leu-
kemic cells of all types of myeloid malignancies. Boje-
sen et al [10] found that GRAF promoter was
hypermethylated in 38% cases with AML and MDS but
not in healthy individuals, however, they did not detect
the GRAF transcript in primary leukemic cells of AML
and MDS. GRAF contains a centrally located GTPase-
activating protein (GAP) domain, followed by a serine/
proline rich domain and a carboxy-terminal Srchomol-
ogy 3 (SH3) domain. GRAF acts as a negative regulator
of RhoA because the GRAF GAP domain enhances
GTP hydrolysis of both Cdc42 and RhoA in vitro [7].
Rho family GTPases play a role in the growth control
besides regulating the organization of the actin cytos-
keleton [18,19]. RhoA inhibits p21Cip1, p27Kip and
p16Ink4 activities, permitting cell cycle progression
[20-24]. Furthermore, RhoA has been shown involved
in the regulation of apoptosis, migration, proliferation,
differentiation [18,19]: for example, in vitro, constitu-
tively active RhoA can stimulate transformation. In
normal epithelia, RhoA contributes to the generation
of epithelial polarity and junction assembly and func-
tion but also affects epithelial disruption during tumor
progression [25]. Recently, clinical studies have
revealed the correlation of increased expression of
RhoA and invasion, metastasis and progression of sev-
eral solid tumors including liver, bladder, esophageal,
head and neck, ovary, gastric, testicular, lung and
breast carcinomas [18]. As an upstream regulator, the
loss of function of GRAF might prevent the physiologic
down-regulation of RhoA and lead to the repression of
p21. Then, the GRAF-defective cell will be driven into
the S phase [9]. Several mechanisms, including translo-
cations, allelic loss, insertions and promoter methyla-
tion observed in AML and MDS, can lead to the
inactivation of GRAF [9,10].
The mechanisms responsible for the disease progres-
sion of CML remained poorly understood. Recent stu-
dies have suggested that several alterations promote this
progress, including differentiation arrest caused by the
suppression of translation of the transcription factor
CEBPa induced by the BCR-ABL oncoprotein in CML
cell, increasing genomic instability in CML cell resulting
from the reduced capability of genome surveillance sys-
tem, telomere shortening and loss of tumor suppressor
gene (TSG) such as TP53, retinoblastoma 1, CDKN2A,
DAPK1 and others [16,26,27]. Interestingly, we found
that GRAF transcript was further down-regulated during
CML progression. p210 Bcr-Abl, containing a centrally
located Rho-specific guanine nucleotide exchange fac-
tors (RhoGEF) domain, affects the actin cytoskeleton
assembly and thereby the cellular adhesion and migra-
tion by RhoA signaling pathway [28]. Further studies are
required to elucidate the function of GRAF and RhoA in
the pathogenesis and progression of CML.
Our preliminary results showed that MDS with 5q
deletion might have lower expression of GRAF than
those without 5q deletion. Deleted 5q is a one of com-
mon chromosomal abnormalities in AML and MDS.
Although GRAF maps telomeric to the previously deli-
neated commonly deleted 5(q31) region, Borkhardt et al
found that one allele of GRAF was consistently lost in
all studied 10 patients with 5q deletion and with either
MDS or AML [9]. Besides GRAF deletion, abnormal
methylation of GRAF promoter was also observed in
AML and MDS [10]. These results suggested that hap-
loinsufficiency (i.e., decreased GRAF mRNA expression)
caused by deletion of GRAF allele or promoter methyla-
tion might be instrumental in the development and pro-
gression of hematopoietic malignancies.
In conclusion, GRAF mRNA is decreased in myeloid
malignancies. Whether the GRAF expression level could
improve the stratification or prognostication of patients
with myeloid diseases should be further addressed in future
studies.
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